A 25-year-old healthy woman presented complaining of distortion and a blind spot near the central vision of her left eye of one month duration. One week preceding visual symptom onset, she endorsed night sweats, headache, and new-onset anosmia. The night sweats and headaches lasted 3 days. The anosmia lasted 2 weeks. She had multiple confirmed ill COVID-19 contacts at her workplace before the onset of her symptoms. Best corrected visual acuity was 20/20 and 20/25 in the right and left eyes, respectively. Intraocular pressures, previously documented as normal, were 20 mmHg on the right and 24 mmHg on the left after one month of topical difluprednate therapy. The anterior chambers were both quiet with no cell or flare. Examination of the vitreous revealed rare cell and no haze in both eyes. Dilated fundus examination revealed placoid lesions in the macula and midperiphery of both eyes. Peripheral punched-out scars with Schlaegel lines were also noted. Fundus imaging (Figure 1) demonstrated hypoautofluorescent lesions in the macula and midperiphery of both eyes with irregular hyperautofluorescent borders. Hypofluorescent lesions were observed on indocyanine green angiography in a distribution more widespread in the left eye than appreciated on fundus examination. Fluorescein angiography (FA) demonstrated early progressive staining and leakage from the placoid lesions without significant early blockage. Optical coherence tomography demonstrated bilateral outer retinal disruption (Figure 2). Laboratory evaluation was negative for QuantiFERON-TB gold, HIV, and syphilis antibodies. COVID-19 antibody testing returned positive for IgG. COVID-19 PCR testing was not performed. The patient's systemic symptoms had occurred 4 months following the initial pandemic lockdowns in the United States when the patient's county of origin had reported a total of 450-460 cases per 100,000 inhabitants. Neuroimaging was not pursued due to the resolution of headaches and absence of neurologic symptoms at the time of evaluation. She was treated with a taper of oral prednisone starting at 60 mg. The retinal lesions did not progress, and steroid-sparing therapy with azathioprine (1.5 mg/kg) was initiated at 3 weeks. Visual acuity remained 20/20 in both eyes at 10-month follow-up after completing a 3-month oral prednisone taper and continuing azathioprine.